Jul. 11 at 4:45 PM
$LSTA ASCEND trial data for Lisata Therapeutics’ certepetide in metastatic pancreatic cancer (mPDAC) is clinically meaningful and scientifically promising Cohort B (newest update – June 2025)
6-month progression-free survival (6MPFS):
Certepetide arm: 60.8%
Placebo arm: 25%
+35.8% absolute improvement — this is very strong for mPDAC.
Median PFS:
Certepetide: 7.5 months
Placebo: 4.7 months
~60% relative improvement — clinically meaningful.
Objective Response Rate (ORR):
Certepetide: 45.2%
Placebo: 19%
More than doubling the response rate, which is rare in pancreatic cancer. ot
$SLNO $VKTX $BWAY $SGMT etc
